Literature DB >> 17124551

Measuring quality of life in rheumatic conditions.

Janine G Walker1, Geoffrey O Littlejohn.   

Abstract

Musculoskeletal disorders often have associated pain, functional impairment and work disability, and, not surprisingly, are the most common reasons for utilizing healthcare resources. Rheumatoid arthritis (RA) and fibromyalgia (FM) are causes of musculoskeletal pain and disability. Research indicates that there is a widespread impact of RA and FM on physical, psychological and social factors in affected individuals, and thus, outcome measures that encompass multiple aspects of quality of life are needed. Generic measures of quality of life identify associations between physical conditions and mental health and highlight the need to address psychological functioning to ultimately improve the individuals' quality of life.

Entities:  

Mesh:

Year:  2006        PMID: 17124551      PMCID: PMC1847465          DOI: 10.1007/s10067-006-0450-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


Musculoskeletal disorders often have associated pain, functional impairment and work disability, and, not surprisingly, are the most common reasons for utilizing healthcare resources [1, 2]. Rheumatoid arthritis (RA) and fibromyalgia (FM) are among the most common causes of musculoskeletal pain and disability. They are estimated in community studies to affect 0.5–1 and 2–6% of the population, respectively [3-5]. These two conditions differ in a number of ways: In particular, RA has a clear pathophysiology with a range of clinical measures being able to indicate its presence, whereas the biological basis for FM is less defined with no “gold standard” test available. Despite this difference, these two rheumatic conditions share a range of associated outcomes. These include not only pain and fatigue but also difficulties with activities of daily living, ranging from basic and intermediate functions through to more complex tasks such as paid employment and social roles, e.g. child rearing [2, 6]. Further, RA and FM are associated with poor psychological functioning with 20 to 60% reporting depressive symptoms [7-9]. It is clear that there is a widespread impact of RA and FM on physical, psychological and social factors in affected individuals, and thus, outcome measures that encompass multiple aspects of quality of life are needed. In this volume, Birtane et al. [10] study the use of a generic measure of physical and psychological functioning in patients with RA and FM and thus provide insights on the quality of life outcomes in these disorders. Generic and self-report measures of quality of life provide a wealth of information regarding the experience of individuals with rheumatic conditions that medical and observational measures cannot capture [11]. One such measure is the Medical Outcomes Survey 36 Items (SF-36) [12], which is a self-report multidimensional measure of quality of life that has been used extensively in RA and FM research [13, 14]. The SF-36 includes subscales across eight dimensions of health and well-being, including physical functioning, role physical, role emotional, bodily pain, general health, vitality, social functioning and mental health. Scores for all subscales are expressed on a scale of 0 to 100, with a higher score indicating a better state of health. It has good reliability and validity for both clinical and healthy community-based samples [15]. A generic measure of quality of life can offer a number of insights into the impact of rheumatic conditions on everyday functioning. The SF-36 provides the opportunity for interesting comparisons of the quality of life between healthy individuals and those with rheumatic conditions and other chronic physical conditions. Studies indicate that those with RA and FM, almost invariably, have reduced or compromised quality of life compared to healthy age-matched controls. Both RA and FM have a similar impact on psychological and physical functioning and social roles as other chronic conditions that contribute to the global burden of diseases, such as heart disease, chronic obstructive pulmonary disease and diabetes [10, 16, 17]. These findings have implications on health policy and allocation of funding for both healthcare and research. For instance, musculoskeletal conditions affect more than 17% of the community and 60% of working-aged adults, with projections indicating that arthritis will affect up to 20% of people by 2020 [18]. The prevalence, cost and burden of musculoskeletal disorders indicate that policymakers need to address the impact on economies, healthcare systems and society at large. For instance, if a public health intervention in 2005 enabled the onset of arthritis to be delayed by 10 years, the age-related incidence rates would be reduced by 11.1% before 2020 [18]. The burden of musculoskeletal disorders and issues of impaired quality of life have become an international health priority with initiatives such as the Bone and Joint Decade launched by the World Health Organization (WHO). Birtane’s use of a generic measure of quality of life highlights the fact that FM, a condition with unclear pathophysiology, is associated with impaired quality of life to a similar extent as RA. This is in keeping with the recent models of quality of life or disability that place less emphasis on disease processes, pathophysiology and/or structural damage. Previous models of outcomes for rheumatic conditions have a strong biomedical focus with many models of disability or quality of life having an implicit assumption that there is a linear relationship between disease processes and disability. Attempting to use such models of disability by reading from left to right has obvious shortcomings because there are many instances such as FM that do not have a fully identifiable disease process [19]. Indeed, focusing on pathophysiology and functional ability in a limited context without consideration of the individual’s everyday tasks and roles sheds little light on the quality of life [20]. Newer approaches to examining disability acknowledge the roles of demographic, physiological, psychological, social and environmental factors acting as buffers and exacerbators of poor outcomes for chronic physical conditions [2]. The International Classification of Functioning (ICF) promoted by the WHO incorporates a broader biopsychosocial framework of disability, health and health-related states [21]. Indeed, the ICF takes a neutral stand with regard to aetiology and allows researchers to arrive at causal inferences using appropriate scientific methods. The ICF attempts to dislodge assumptions that the body level dysfunctioning, classified as impairments, is the fundamental dimension of disability and quality of life [21-23]. In other words, the quality of life in both RA and FM is not contingent on aetiology. The presence of a disability implies a cause, but the cause may not be sufficient to explain the resulting quality of life [21, 24, 25]. Measures such as the SF-36 provide the building blocks to create models of quality of life and study the different perspectives of this process across a range of chronic physical conditions as well as healthy individuals. Within this framework, using generic measures of quality of life can offer opportunities to frame research and interventions that appropriately target the quality of life of individuals with musculoskeletal disorders. Using this approach, Birtane et al. [10] identified in patients with RA and FM that the incidence of poor physical and psychological functioning is almost invariably greater than for healthy controls. Additionally, higher depression levels are evident in patients with FM compared to those with RA. It is not surprising that FM is associated with the worst psychological functioning, given that depression is often evident in individuals with FM [26]. These observations are consistent with previous findings, which indicate that significant depressive symptoms are reported by up to 60% of individuals with chronic physical conditions. Addressing poor psychological functioning, especially depression, in musculoskeletal conditions is critical due to its impact on the condition itself. Reciprocal relationships can occur between depression and pain and disability leading to a cycle of poor mental and physical health. Depression is related to poor treatment compliance and increased morbidity and mortality in rheumatic conditions [27]. Measures such as the SF-36 clearly identify the associations between chronic physical conditions and mental health and further highlight the importance of addressing psychological functioning in both research and interventions to ultimately improve the individuals’ quality of life. RA and FM are of course not mutually exclusive. The pathophysiology of each disorder is different, and many patients with RA also have FM, as do many other patients with a variety of chronic rheumatic diseases. The substrate of FM lies in the pain system, which can be functionally activated by distress, a common feature of chronic painful and disabling disorders. How much of the FM mechanism contributes to the low quality of life of RA? Further exploration of the mechanisms causing FM, with its resultant highly significant effect on the quality of life, will have a great impact on the management of not only FM itself but also RA and related musculoskeletal conditions.
  23 in total

1.  Identification of relevant ICF categories in patients with chronic health conditions: a Delphi exercise.

Authors:  Martin Weigl; Alarcos Cieza; Christina Andersen; Barbara Kollerits; Edda Amann; Gerold Stucki
Journal:  J Rehabil Med       Date:  2004-07       Impact factor: 2.912

2.  ICF Core Sets for chronic widespread pain.

Authors:  Alarcos Cieza; Gerold Stucki; Martin Weigl; Lajos Kullmann; Thomas Stoll; Leonard Kamen; Nenad Kostanjsek; Nicolas Walsh
Journal:  J Rehabil Med       Date:  2004-07       Impact factor: 2.912

3.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

4.  Seven chronic conditions: their impact on US adults' activity levels and use of medical services.

Authors:  L M Verbrugge; D L Patrick
Journal:  Am J Public Health       Date:  1995-02       Impact factor: 9.308

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  The impact of rheumatoid arthritis on the homemaker.

Authors:  S T Reisine; C Goodenow; K E Grady
Journal:  Soc Sci Med       Date:  1987       Impact factor: 4.634

7.  Profile of arthritis disability: II.

Authors:  Lois M Verbrugge; Lucia Juarez
Journal:  Arthritis Rheum       Date:  2006-02-15

8.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee.

Authors:  F Wolfe; H A Smythe; M B Yunus; R M Bennett; C Bombardier; D L Goldenberg; P Tugwell; S M Campbell; M Abeles; P Clark
Journal:  Arthritis Rheum       Date:  1990-02

9.  Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample.

Authors:  Lachlan A McWilliams; Brian J Cox; Murray W Enns
Journal:  Pain       Date:  2003-11       Impact factor: 6.961

10.  Sociodemographic factors and the outcome of rheumatoid arthritis in young women.

Authors:  T P Vliet Vlieland; N A Buitenhuis; D van Zeben; J P Vandenbroucke; F C Breedveld; J M Hazes
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103

View more
  14 in total

1.  Jumping into the deep-end: results from a pilot impact evaluation of a community-based aquatic exercise program.

Authors:  Anna L Barker; Jason Talevski; Renata T Morello; Genevieve A Nolan; Renee D De Silva; Andrew M Briggs
Journal:  Clin Rheumatol       Date:  2015-10-29       Impact factor: 2.980

2.  Health-related quality of life in ankylosing spondylitis, fibromyalgia syndrome, and rheumatoid arthritis: a comparison with a selected sample of healthy ındividuals.

Authors:  Nimet Ovayolu; Ozlem Ovayolu; Gülendam Karadag
Journal:  Clin Rheumatol       Date:  2010-11-06       Impact factor: 2.980

3.  Baseline HAQ and SF-36 questionnaire scores cannot predict clinical remission, radiographic progression or the need for biological therapy in a three-year prospective study of a Brazilian early rheumatoid arthritis cohort.

Authors:  Licia Maria Henrique da Mota; Leopoldo Luiz Dos Santos Neto; Ana Cristina V Oliveira; Ivânio Alves Pereira; Rufus W Burlingame; Henri A Ménard; Ieda Maria Magalhães Laurindo
Journal:  Rheumatol Int       Date:  2011-12-25       Impact factor: 2.631

Review 4.  Statin treatment for rheumatoid arthritis: a promising novel indication.

Authors:  Kosmas I Paraskevas
Journal:  Clin Rheumatol       Date:  2007-12-08       Impact factor: 2.980

5.  A case-control study of oral diseases and quality of life in individuals with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Brena Rodrigues Manzano; Paulo Sérgio da Silva Santos; Matheus Henrique Bariquelo; Nathália Rodrigues Germano Merlini; Heitor Marques Honório; Cássia Maria Fischer Rubira
Journal:  Clin Oral Investig       Date:  2020-08-15       Impact factor: 3.573

6.  A comparative evaluation of health related quality of life and depression in patients with fibromyalgia syndrome and rheumatoid arthritis.

Authors:  Berna Tander; Kivanc Cengiz; Gamze Alayli; Ilker Ilhanli; Sevgi Canbaz; Ferhan Canturk
Journal:  Rheumatol Int       Date:  2008-03-04       Impact factor: 2.631

7.  Diagnosing fibromyalgia in rheumatoid arthritis: The importance of assessing disease activity.

Authors:  Ayşegül Kılıçarslan; Fatma Gül Yurdakul; Hatice Bodur
Journal:  Turk J Phys Med Rehabil       Date:  2018-05-15

8.  Comparisons of Body Image Perceptions of a Sample of Black and White Women with Rheumatoid Arthritis and Fibromyalgia in the US.

Authors:  Josephine E A Boyington; Britta Schoster; Leigh F Callahan
Journal:  Open Rheumatol J       Date:  2015-01-31

9.  Validation of the GALS musculoskeletal screening exam for use in primary care: a pilot study.

Authors:  Karen A Beattie; Raja Bobba; Imaan Bayoumi; David Chan; Inge Schabort; Pauline Boulos; Walter Kean; Joyce Obeid; Ruth McCallum; George Ioannidis; Alexandra Papaioannou; Alfred Cividino
Journal:  BMC Musculoskelet Disord       Date:  2008-08-27       Impact factor: 2.362

10.  The Association between Chronic Widespread Musculoskeletal Pain, Depression and Fatigue Is Genetically Mediated.

Authors:  Andrea Burri; Soshiro Ogata; Gregory Livshits; Frances Williams
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.